• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

J&J Opens Doxil Rationing Program To New Patients

Article

Johnson & Johnson (JNJ) will begin allowing new patients to enroll in a rationing program to receive the cancer drug Doxil because some of the limited, remaining supply has been freed up.

In a notice posted on the Doxil website Wednesday, J&J said it will reopen enrollment in the program starting Friday because some prior requests from doctors have changed and freed up supplies. Some doctors told J&J that Doxil supplies earmarked for patients already enrolled were no longer needed or they opted patients out of the program, the company said.

About 1,000 patients are now receiving Doxil--which treats ovarian and other cancers--through an allocation program that J&J created last year to address a product shortage.

Read the full story: http://hcp.lv/K6a9Bp

Source: Morningstar

Related Videos
Rashon Lane, PhD, MA
Dr Julie Patterson, National Pharmaceutical Council
Diana Isaacs, PharmD
Beau Raymond, MD
Binod Dhakal, MD, Medical College of Wisconsin, lead CARTITUDE-4 investigator
Dr Sophia Humphreys
Robert Zimmerman, MD
Video 15 - "Ensuring Fair Cardiovascular Care for All: Concluding Perspectives on Disparities and Inclusion"
Shawn Tuma, JD, CIPP/US, cybersecurity and data privacy attorney, Spencer Fane LLP
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.